抗寄生虫新型药物研究进展

Advances in research on new antiparasitic drugs

寄生虫病尤其是食源性寄生虫病对人类的健康危害巨大,控制寄生虫病不仅要依靠预防,而且需要对病人和感染者进行有效的治疗。目前临床上可供选择治疗寄生虫病的药物十分有限,除青蒿素等为国家自主产权药物外,其他都为国外专利性药物。因此,研发来源丰富,绿色环保,成本低廉,价格合理,低毒高效,具有我国自主知识产权,性能优异,结构新颖的活性化合物具有重要的意义。由于治疗寄生虫的药物仍然十分有限,本文就目前国内外临床应用和开发的螺旋吲哚酮、夹竹桃和毛叶巴豆混合提纯物、地衣酸提纯物、17-AAG、节莎草L提取物、类维A酸X受体拮抗剂-HX531、沃特曼内酯F等新型抗寄生虫病药物研究应用现状进行了综述。

Parasitic diseases,and especially food-borne parasitic diseases,greatly harm the health of human beings.Controlling these diseases depends on prevention and also requires effective treatment of patients and carriers.Available drugs are greatly limited.The Chinese Government holds the patients to some drugs such as artemisinin,but the rest are all patented drugs from overseas.Thus,new drugs with rich sources of research and development,that are environmentally friendly,that are low-cost,that are reasonably priced,that have a low level of toxicity and high level of efficacy,that have intellectual property rights held in China,that have excellent performance,and that have active compounds with a novel structure are of great significance.State-owned brands of new drugs can be created in China,allowing this country to reach an advanced level in this field in comparison to other countries.Since the availability of antiparasitic drugs is fairly limited,this review discusses the current clinical use and development of drugs such as KAE609,leaves of Acokanthera schimperi and Croton macrostachyus,usnic acid,17-AAG,Cyperus articulatus L,HX53,and wortmannilactone F.